Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet) Press release
Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022 Press release
Galderma launches a virtual experience this Rosacea Awareness Month showcasing how the condition goes beyond the visible with Rosacea Space Press release
Galderma to present new clinical data and high patient satisfaction across their portfolio of dermal fillers, collagen biostimulators and liquid neuromodulators at AMWC 2022 Press release
Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting Press release